Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021 Range of presentations highlight the company s research productivity and broad precision therapy portfolio
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the company s precision oncology and hematology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2021. Collectively, the planned data presentations will highlight the potential of Blueprint Medicines precision therapies to deliver transformative benefits to broad patient populations with systemic mastocytosis, non-small cell lung cancer and cyclin E-aberrant cancers.
Additional preclinical data on ZN-c3 and the Company’s EGFR inhibitor, ZN-e4, will be presented as poster presentationsNEW YORK and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. The meeting will be held virtually on April 10-15 and May 17-21, 2021. “The important data we are presenting at AACR supports the ability of our Integrated Discovery Engine to develop differentiated oncology therapeutic candidates across diverse cancer targets and types,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals. “We e
(2)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021(Nasdaq: MRUS) ( Merus , the Company , we , or our ), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021.
E-Poster Presentation:
Title: The HER2×HER3 bi-specific antibody zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Abstract #: 956
Session Title: Biological Therapeutic Agents
Title: Zenocutuzumab: An antibody that can overcome HER3 mediated HRG signaling in tumor cells by docking on HER2
Posted March 10, 2021
New research from the University at Buffalo suggests that breast cancer patients who drink sugar-sweetened beverages regularly are at increased risk for death from any cause and breast cancer in particular.
Compared to women who never or rarely drank non-diet soda, those who reported drinking non-diet soda five times or more per week had a 62% higher likelihood of dying from any causes, and were 85% more likely to die from breast cancer specifically. The findings were published online ahead of print in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Image credit: U.S. Air Force photo by Senior Airman Tiffany Trojca via holloman.af.mil, Public Domain
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.